Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | FGF1 | P05230 | 1/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521264 | 0.79 | PYGB (0.49) | PYGBGAA | |
| SCHEMBL1333011 | 0.79 | PYGB (0.68) | PYGBGAA | |
| SCHEMBL6683934 | 0.77 | PYGB (0.71) | PYGBGAA | |
| SCHEMBL14106417 | 0.77 | PYGB (0.71) | PYGBGAA | |
| SCHEMBL18376631 | 0.77 | PYGB (0.71) | PYGBGAA | |
| SCHEMBL783243 | 0.77 | LGALS8 (0.41) | PYGB | |
| Glycine SCHEMBL639188 | 0.76 | ADORA1 (0.40) | — | |
| SCHEMBL2045173 | 0.74 | SMPD1 (0.45) | — | |
| SCHEMBL5378658 | 0.74 | SMPD1 (0.48) | — | |
| SCHEMBL30237668 | 0.74 | SMPD1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4674946-A1 | NOVEL GENETIC RECOMBINATION MARKER AND USE THEREOF | KAO CORPORATION (JP) | 2026-01-07 | — | — | EP | claimed |
| WO-2024123109-A1 | MICROORGANISM PRODUCING PURINE NUCLEOTIDES AND METHOD FOR PRODUCING PURINE NUCLEOTIDES USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | claimed |
| WO-2024123108-A1 | PURINE NUCLEOTIDE-PRODUCING MICROORGANISM AND METHOD FOR PRODUCTION OF PURINE NUCLEOTIDE USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | claimed |
| WO-2024123101-A1 | MICROORGANISM PRODUCING PURINE NUCLEOTIDE, AND METHOD FOR PRODUCING PURINE NUCLEOTIDE USING SAME | 씨제이제일제당 (주) | 2024-06-13 | — | — | WO | claimed |
| US-8158360-B2 | Effects of inhibitors of FGFR3 on gene transcription | NOVARTIS AG (CH) | 2012-04-17 | — | — | US | claimed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | claimed |
| EP-1668154-B1 | METHODS USEFUL FOR DETECTING AN ALTERATION IN A LOCUS COPY NUMBER | TRISOGEN BIOTECHNOLOGY LTD PAR (IL) | 2008-11-26 | — | — | EP | claimed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | claimed |
| EP-1404706-A2 | MYCOBACTERIAL ANTIGENS EXPRESSED DURING LATENCY | Health Protection Agency (GB) | 2004-04-07 | — | — | EP | claimed |
| WO-2003004520-A2 | MYCOBACTERIAL ANTIGENS EXPRESSED DURING LATENCY | HEALTH PROTECTION AGENCY (GB) | 2003-01-16 | — | — | WO | claimed |
| EP-0973935-A2 | TARGET GENES FOR ALLELE-SPECIFIC DRUGS | Variagenics, Inc. (US) | 2000-01-26 | — | — | EP | claimed |
| WO-1998041648-A9 | TARGET GENES FOR ALLELE-SPECIFIC DRUGS | — | 1999-01-07 | — | — | WO | claimed |
| WO-1998041648-A2 | TARGET GENES FOR ALLELE-SPECIFIC DRUGS | VARIAGENICS, INC. (US) | 1998-09-24 | — | — | WO | claimed |
| US-20260083833-A1 | IMMUNOGENIC PROTEINS FROM BORDETELLA PERTUSSIS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-26 | — | — | US | disclosed |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-10 | — | — | US | disclosed |
| US-12559774-B2 | CRISPR enzymes and systems | THE BROAD INSTITUTE, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| CN-1046285-C | Condensed heterocyclic glutamic acid derivatives as antiproliferative agents | AGOURON PHARMA (US) | 1999-11-10 | — | — | CN | disclosed |
| CN-1159193-A | Compounds useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMA (US) | 1997-09-10 | — | — | CN | disclosed |
| CN-1154110-A | Compounds useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMA (US) | 1997-07-09 | — | — | CN | disclosed |
| CN-1117295-A | Condensed heterocyclic glutamic acid derivatives as antiproliferative agents | AGOURON PHARMA (US) | 1996-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083833-A1 | IMMUNOGENIC PROTEINS FROM BORDETELLA PERTUSSIS | HLA-DRB1, CD74, CD4 | PYGB 2280/4885GAA 4553/4885FGF1 4256/4885 |
| US-12559774-B2 | CRISPR enzymes and systems | CPSF1, CPSF6, FEN1 | PYGB 576/4885GAA 415/4885FGF1 4644/4885 |
| US-12569439-B2 | Bottom-up assembly of synthetic extracellular vesicles | EXOSC10, PLTP, EXOSC9 | PYGB 4007/4885GAA 4314/4885FGF1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.